139 related articles for article (PubMed ID: 9448589)
1. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus.
Sturfelt G; Roux-Lombard P; Wollheim FA; Dayer JM
Br J Rheumatol; 1997 Dec; 36(12):1283-9. PubMed ID: 9448589
[TBL] [Abstract][Full Text] [Related]
2. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?
Capper ER; Maskill JK; Gordon C; Blakemore AI
Clin Exp Immunol; 2004 Nov; 138(2):348-56. PubMed ID: 15498048
[TBL] [Abstract][Full Text] [Related]
3. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus.
Italiani P; Manca ML; Angelotti F; Melillo D; Pratesi F; Puxeddu I; Boraschi D; Migliorini P
Arthritis Res Ther; 2018 Feb; 20(1):27. PubMed ID: 29422069
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus.
Chang DM
Immunol Invest; 1997; 26(5-7):649-59. PubMed ID: 9399106
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity.
Suzuki H; Takemura H; Kashiwagi H
Arthritis Rheum; 1995 Aug; 38(8):1055-9. PubMed ID: 7639800
[TBL] [Abstract][Full Text] [Related]
6. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients.
Liou LB
Clin Exp Rheumatol; 2001; 19(5):515-23. PubMed ID: 11579710
[TBL] [Abstract][Full Text] [Related]
7. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M
Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031
[TBL] [Abstract][Full Text] [Related]
8. Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels.
Liou LB
Clin Exp Rheumatol; 2003; 21(4):437-44. PubMed ID: 12942694
[TBL] [Abstract][Full Text] [Related]
9. Do high sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosuspatients?
Umare V; Nadkarni A; Nadkar M; Rajadhyksha A; Khadilkar P; Ghosh K; Pradhan VD
J Postgrad Med; 2017; 63(2):92-95. PubMed ID: 27531690
[TBL] [Abstract][Full Text] [Related]
10. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?
Spronk PE; ter Borg EJ; Limburg PC; Kallenberg CG
Clin Exp Immunol; 1992 Oct; 90(1):106-10. PubMed ID: 1395090
[TBL] [Abstract][Full Text] [Related]
12. Performance of cytokine models in predicting SLE activity.
Ruchakorn N; Ngamjanyaporn P; Suangtamai T; Kafaksom T; Polpanumas C; Petpisit V; Pisitkun T; Pisitkun P
Arthritis Res Ther; 2019 Dec; 21(1):287. PubMed ID: 31842967
[TBL] [Abstract][Full Text] [Related]
13. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE.
Tripathy R; Panda AK; Das BK
Lupus; 2015 Jan; 24(1):82-9. PubMed ID: 25253568
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis.
De Benedetti F; Pignatti P; Massa M; Sartirana P; Ravelli A; Martini A
Clin Exp Rheumatol; 1995; 13(6):779-84. PubMed ID: 8835254
[TBL] [Abstract][Full Text] [Related]
15. IL-1RA in refractory systemic lupus erythematosus.
Moosig F; Zeuner R; Renk C; Schröder JO
Lupus; 2004; 13(8):605-6. PubMed ID: 15462491
[TBL] [Abstract][Full Text] [Related]
16. Increased serum IL-36α and IL-36γ levels in patients with systemic lupus erythematosus: Association with disease activity and arthritis.
Mai SZ; Li CJ; Xie XY; Xiong H; Xu M; Zeng FQ; Guo Q; Han YF
Int Immunopharmacol; 2018 May; 58():103-108. PubMed ID: 29571080
[TBL] [Abstract][Full Text] [Related]
17. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves' ophthalmopathy undergoing orbital radiotherapy.
Hofbauer LC; Mühlberg T; König A; Heufelder G; Schworm HD; Heufelder AE
J Clin Endocrinol Metab; 1997 Jul; 82(7):2244-7. PubMed ID: 9215301
[TBL] [Abstract][Full Text] [Related]
18. Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury.
Mandrup-Poulsen T; Wogensen LD; Jensen M; Svensson P; Nilsson P; Emdal T; Mølvig J; Dinarello CA; Nerup J
Crit Care Med; 1995 Jan; 23(1):26-33. PubMed ID: 8001382
[TBL] [Abstract][Full Text] [Related]
19. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus.
Chun HY; Chung JW; Kim HA; Yun JM; Jeon JY; Ye YM; Kim SH; Park HS; Suh CH
J Clin Immunol; 2007 Sep; 27(5):461-6. PubMed ID: 17587156
[TBL] [Abstract][Full Text] [Related]
20. Potential biomarkers for diagnosis and assessment of disease activity in systemic lupus erythematosus.
Zhang X; Liu C; Yang J; Ren H; Zhang J; Chen S; Ren J; Zhou L
Int Immunopharmacol; 2022 Oct; 111():109155. PubMed ID: 36029665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
